Clinical trialNCT00630877CompletedPhase 3Interventional

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

SponsorAbbottEnrollment276Dyslipidemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin (ASA) daily for 6 weeks. The FAST is a questionnaire that was developed to provide a detailed assessment of flushing symptoms and their impact in patients receiving niacin therapy. The effect of aspirin on flushing symptoms, as measured by the FAST, was also evaluated.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Roopal Thakkar, MD
Abbott
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Birmingham, Alabama, United States
Facility name not stated
Anaheim, California, United States
Facility name not stated
Walnut Creek, California, United States
Facility name not stated
Denver, Colorado, United States
Facility name not stated
Brooksville, Florida, United States
Facility name not stated
Daytona Beach, Florida, United States
Facility name not stated
Hollywood, Florida, United States
Facility name not stated
Jacksonville, Florida, United States
Facility name not stated
Largo, Florida, United States
Facility name not stated
Miami, Florida, United States
Facility name not stated
Pembroke Pines, Florida, United States
Facility name not stated
Boise, Idaho, United States
Facility name not stated
Chicago, Illinois, United States
Facility name not stated
Arkansas City, Kansas, United States
Facility name not stated
Topeka, Kansas, United States
Facility name not stated
Wichita, Kansas, United States
Facility name not stated
Wichita, Kansas, United States
Facility name not stated
St Louis, Missouri, United States
Facility name not stated
Las Vegas, Nevada, United States
Facility name not stated
Durham, North Carolina, United States
Facility name not stated
High Point, North Carolina, United States
Facility name not stated
Salisbury, North Carolina, United States
Facility name not stated
Statesville, North Carolina, United States
Facility name not stated
Cincinnati, Ohio, United States
Facility name not stated
Portland, Oregon, United States
Facility name not stated
Duncansville, Pennsylvania, United States
Facility name not stated
Harleysville, Pennsylvania, United States
Facility name not stated
Pittsburgh, Pennsylvania, United States
Facility name not stated
Greer, South Carolina, United States
Facility name not stated
Austin, Texas, United States
Facility name not stated
Carrollton, Texas, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
San Antonio, Texas, United States
Facility name not stated
San Antonio, Texas, United States
Facility name not stated
Magna, Utah, United States
Facility name not stated
Murray, Utah, United States
Facility name not stated
Sandy City, Utah, United States
Facility name not stated
Gig Harbor, Washington, United States
Facility name not stated
Menomonee Falls, Wisconsin, United States
Facility name not stated
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aspirin →Aspirin placeboNiacin extended-releaseNiacin extended-release placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Feb 2008
Primary completion: 30 Jun 2008
Completion: 30 Jun 2008
Last update posted: 9 Oct 2009
Registered enrollment: 276
Registry id: NCT00630877

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.